GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigene AG (OTCPK:MDGEF) » Definitions » Net-Net Working Capital

MDGEF (Medigene AG) Net-Net Working Capital : $0.38 (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Medigene AG Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Medigene AG's Net-Net Working Capital for the quarter that ended in Jun. 2024 was $0.38.

The industry rank for Medigene AG's Net-Net Working Capital or its related term are showing as below:

MDGEF's Price-to-Net-Net-Working-Capital is ranked better than
56.46% of 898 companies
in the Biotechnology industry
Industry Median: 4.125 vs MDGEF: 3.29

Medigene AG Net-Net Working Capital Historical Data

The historical data trend for Medigene AG's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigene AG Net-Net Working Capital Chart

Medigene AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.37 0.85 0.75 1.72 0.53

Medigene AG Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 1.72 0.47 0.53 0.38

Competitive Comparison of Medigene AG's Net-Net Working Capital

For the Biotechnology subindustry, Medigene AG's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medigene AG's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Medigene AG's Price-to-Net-Net-Working-Capital falls into.



Medigene AG Net-Net Working Capital Calculation

Medigene AG's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(18.183+0.75 * 0.454+0.5 * 0-11.613
-0-0)/12.933
=0.53

Medigene AG's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jun. 2024 is calculated as

Net-Net Working Capital(Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(15.096+0.75 * 0.537+0.5 * 0-9.849
-0-0)/14.7376
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Medigene AG  (OTCPK:MDGEF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Medigene AG Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Medigene AG's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Medigene AG Business Description

Traded in Other Exchanges
Address
Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.

Medigene AG Headlines

From GuruFocus

Q4 2020 Medigene AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2023 Medigene AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2021 Medigene AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2023 Medigene AG Earnings Call Transcript

By GuruFocus Research 03-29-2024

Q2 2024 Medigene AG Earnings Call Transcript

By GuruFocus Research 08-15-2024

Q2 2022 Medigene AG Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2022 Medigene AG Earnings Call Transcript

By GuruFocus Research 02-14-2024